A study in the Journal of Nuclear Medicine found radioimmunotherapy with a combination of Cu-64 labeled DOTA-cetuximab and cisplatin may halt colorectal tumor growth. Researchers evaluated therapeutic response in mice with KRAS-mutated HCT116 tumors. "Together, these data suggest that Cu-64 specifically delivered to epidermal growth factor receptor-positive tumors by cetuximab can suppress tumor growth despite the KRAS status and present opportunities for personalized clinical treatment strategies in colorectal cancer," the authors wrote.

Related Summaries